OSE Immunotherapeutics Expands its Collaboration with MAbSilico to Use Artificial Intelligence to Accelerate Drug Development of Novel Antibody Therapeutics

OSE is advancing an “Immunotherapy 2.0” future by leveraging MAbSilico’s artificial intelligence-powered software solutions and professional services to accelerate and further optimize the development of new therapeutic monoclonal antibodies. OSE and MAbSilico joined their efforts to demonstrate the power of a fully computational in silico Antibody Discovery and Design platform. The expanded collaboration agreement will […]

Continue Reading

OSE Immunotherapeutics Presentation at H.C. Wainwright BIOCONNECT 2021 Virtual Conference

NANTES, France, Jan. 05, 2021 (GLOBE NEWSWIRE) — OSE Immunotherapeutics (ISIN: FR0012127173; Mnemo: OSE) today announced that Alexis Peyroles, Chief Executive Officer, will provide an overview of the Company’s business at the upcoming H.C. Wainwright BIOCONNECT virtual conference to be held January 11-14, 2021. The presentation will be available for on-demand listening beginning Monday, January […]

Continue Reading

OSE Immunotherapeutics Announces Enrolment of First Patient with Ulcerative Colitis in Phase 2 Trial Testing Anti-IL-7 Receptor Antagonist OSE-127/S95011

NANTES, France, Dec. 21, 2020 (GLOBE NEWSWIRE) — OSE Immunotherapeutics (ISIN: FR0012127173; Mnemo: OSE) today announced enrolment of the first patient in its Phase 2 clinical trial evaluating the benefits of anti-IL-7 receptor antagonist OSE-127/S95011 for moderate to severe active ulcerative colitis patients. Alexis Peyroles, Chief Executive Officer of OSE Immunotherapeutics, comments: “The first patient […]

Continue Reading

OSE Immunotherapeutics and Nantes University Hospital Announce Initiation of a Phase 1/2 Clinical Trial to Evaluate CD28 Antagonist FR104 in Patients Undergoing Renal Transplantation

University Hospital of Nantes will sponsor and conduct the clinical trial OSE Immunotherapeutics will provide its FR104 product Post-transplant immune response is a key therapeutic issue for patients and a new development indication for FR104 NANTES, France, Dec. 03, 2020 (GLOBE NEWSWIRE) — OSE Immunotherapeutics (ISIN: FR0012127173; Mnémo: OSE), and Nantes University Hospital (CHU de […]

Continue Reading

OSE Immunotherapeutics to Present at SITC Annual Meeting and at Additional International Immuno-Oncology Summits

Presentations to focus on myeloid cells and “Don’t Eat Me” signal as a novel emerging pathway of interest in immuno-oncology NANTES, France, Nov. 09, 2020 (GLOBE NEWSWIRE) — OSE Immunotherapeutics (ISIN: FR0012127173; Mnemo: OSE) has been invited to provide an update on its R&D programs in immuno-oncology at several dedicated international conferences in October and […]

Continue Reading

OSE Immunotherapeutics to Present at SITC Annual Meeting and at Additional International Immuno-Oncology Summits

Presentations to focus on myeloid cells and “Don’t Eat Me” signal as a novel emerging pathway of interest in immuno-oncology NANTES, France, Nov. 09, 2020 (GLOBE NEWSWIRE) — OSE Immunotherapeutics (ISIN: FR0012127173; Mnemo: OSE) has been invited to provide an update on its R&D programs in immuno-oncology at several dedicated international conferences in October and […]

Continue Reading

OSE Immunotherapeutics to Present at SITC Annual Meeting and at Additional International Immuno-Oncology Summits

Presentations to focus on myeloid cells and “Don’t Eat Me” signal as a novel emerging pathway of interest in immuno-oncology NANTES, France, Nov. 09, 2020 (GLOBE NEWSWIRE) — OSE Immunotherapeutics (ISIN: FR0012127173; Mnemo: OSE) has been invited to provide an update on its R&D programs in immuno-oncology at several dedicated international conferences in October and […]

Continue Reading